LQDA trades 4.3% above Wall Street's consensus target of $68.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LQDA achieves its forward estimates and maintains a stable P/E multiple of 21.2x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Liquidia Corporation (LQDA) has a Wall Street consensus price target of $68.00, based on estimates from 7 covering analysts. With the stock currently trading at $71.07, this represents a potential downside of -4.3%. The company has a market capitalization of $6.32B.
Analyst price targets range from a low of $60.00 to a high of $75.00, representing a 22% spread in expectations. The median target of $68.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LQDA trades at a trailing P/E of -88.8x and forward P/E of 21.2x. Analysts expect EPS to grow +1417.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.75, with bear and bull scenarios of $5.51 and $11.53 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
UTHRUnited Therapeutics Corporation | $22.8B | $536.59 | $636.83 | +18.7% | Buy | 18.9x | 30 |
MNKDMannKind Corporation | $1.2B | $3.94 | $8.50 | +115.7% | Buy | — | 19 |
INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
INSMInsmed Incorporated | $20.8B | $95.80 | $204.42 | +113.4% | Buy | — | 35 |
NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
PBYIPuma Biotechnology, Inc. | $385M | $7.56 | — | — | Buy | 26.1x | 19 |
KALAKALA BIO, Inc. | $79M | $3.61 | $18.25 | +405.5% | Buy | — | 9 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
Quick answers to the most common questions about buying LQDA stock.
Wall Street's consensus price target for LQDA is $68, -4.3% from its current price of $71.07. The below-market target from 7 analysts suggests limited near-term appreciation.
LQDA has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $68 implies -4.3% downside from current levels.
LQDA trades at a forward P/E of 21.2244x, representing a moderate valuation. With analysts targeting $68 (-4.3% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $75 for LQDA, while the most conservative target is $60. The consensus of $68 represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LQDA is moderately covered, with 7 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LQDA stock forecast based on 7 Wall Street analysts shows a consensus price target of $68, with estimates ranging from $60 (bear case) to $75 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.
Our quantitative valuation model calculates LQDA's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
LQDA trades at a forward P/E ratio of 21.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on LQDA, with 1 Sell ratings and a price target of $68 (-4.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LQDA analyst price targets range from $60 to $75, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $68 consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.